Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Axcess (UK) Ltd is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that the portfolio's current prosecution involves multiple technical or administrative tracks within the patent office.
The busiest examiner, WELLS, LAUREN QUINLAN, is handling 1 pending office action. Since there are 2 pending office actions in total, the workload is divided between two examiners. This split across 2 distinct examiners requires the practitioner to manage two separate sets of office communications and deadlines. Each of the 2 pending office actions may require a unique strategy based on the specific examiner's perspective.
The involvement of 2 distinct art units suggests that the 2 pending office actions may be subject to different examination cultures or technical standards. Practitioners must tailor their strategies to the specific requirements of both 2 distinct art units. Successfully resolving the 1 action with WELLS, LAUREN QUINLAN is just one part of the overall strategy for the 2 pending office actions. The presence of 2 distinct examiners provides a level of diversification for the portfolio's prosecution progress.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| ROMERO, KRISTEN WANG | 1 | 68.8% | +31.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17794757 | Cellular Uptake | ROMERO, KRISTEN WANG | 147d overdue |
| 18273754 | EDTA AND EGTA FOR USE IN PRESERVING THE INTEGRITY OF THERAPEUTIC COMPOUNDS | WELLS, LAUREN QUINLAN | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18273754 | EDTA AND EGTA FOR USE IN PRESERVING THE INTEGRITY OF THERAPEUTIC COMPOUNDS | WELLS, LAUREN QUINLAN | 1622 | §102§103§112DP | Non-Final OA | — | Pending | Jul 21, 2023 |
| 17794757 | Cellular Uptake | ROMERO, KRISTEN WANG | 1624 | §112 | Non-Final OA | 147d overdue | Pending | Jul 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial